What a year 2024 has been for Trace Neuroscience, with one of the largest biopharma Series A rounds in recent years funding the development of a treatment for amyotrophic lateral sclerosis (ALS), which affects 5000 people in the UK. UCLB played a crucial role in supporting the intellectual property behind the discovery and facilitating the collaboration between Trace Neuroscience and the academic team at @ucl. Find out more here: https://t.co/bAQSoCghvl

Earlier this year, @UCL spinout company Autolus Therapeutics announced that the U.S. Food and Drug Administration (FDA) had granted marketing approval for AUCATZYL® (obecabtagene autoleucel, obe-cel), for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). UCLB has supported Autolus in protecting and licensing the obe-cel technology, enabling it to attract further capital to fund its development. More here: https://t.co/ZXqNNcT9e4 #BioPharm# #TechTransfer# #Spinouts#